Skip to main content

Phil Aird-Mash appointed as new Chair of JDRF

Phil Aird-Mash, CEO of the ITC Travel Group, Chair of ACC Aviation and Traveltek Ltd has been appointed JDRF’s Chair of the Board of Directors after a competitive recruitment process.
JDRF logo placeholder for author profile picture
Kate Lawton 25 October 2022

Phil Aird Mash

Phil Aird-Mash, CEO of the ITC Travel Group, Chair of ACC Aviation and Traveltek Ltd has been appointed JDRF’s Chair of the Board of Directors after a competitive recruitment process.

Phil has served on the JDRF Board since 2019 and has been Vice Chair since 2021. He was diagnosed with type 1 diabetes at the age of 28.

Personal resonance

He says: “JDRF is a charity close to my heart. I consider myself fortunate that I was diagnosed swiftly and with great support from healthcare professionals and my family and friends. Since this time, I have always given much thought to the impact type 1 has on families, in particular on children who are diagnosed with the condition.

JDRF’s research to find a cure, alongside its work to support and improve the health, wellbeing and quality of life of those affected, has tremendous personal resonance. I am delighted to be able to use my skills, experience and networks to help the cause.”

JDRF’s current chairman David McTurk, will be stepping down from his role at the end of his term of office at the end of December 2022. David has been involved in JDRF for 21 years and as Chair since 2019 he has helped to steer JDRF through the uncertain times of the Covid pandemic.

David says: “JDRF has been a very important part of my life.  However, I have decided that now is the right time for me to step down as I move fully into retirement, and it is an opportunity for fresh thinking and increased impetus on the Board as we face the new challenges ahead of us.

I am delighted that we have been able to appoint Phil Aird-Mash as our new Chair. He is absolutely the right person for the job, and I know very well he will lead JDRF with great vision and determination.”

Continuing our mission to eradicate type 1

JDRF’s Chief Executive Karen adds: “I feel extremely fortunate to have had the opportunity to work with David over the past three years. His energy, experience and enthusiasm for what we do here at JDRF has been invaluable, especially over the course of the pandemic.

While we’ll be incredibly sad to say goodbye to David, I look forward to welcoming Phil into the new role of Chair. Phil takes on this role at an exciting time for JDRF as we look to build on the firm foundation that David has helped us to build. His business acumen and lived experience of Type 1 diabetes will help us to continue our mission to eradicate type 1 and its effects.”

Related news

Read more
Dr Gavin Bewick, a type 1 diabetes researcher working on developing a drug to protect beta cells, in his lab.
Research
12 December 2023

2023 in review – a year of progress and breakthroughs

It's been an incredible year for advancements in type 1 diabetes research and treatments. We take a look at the progress we made in 2023, funded by you, our supporters. 

Read more
Nadia Swann, Wilson Leech and Sarah Johnson
JDRF
1 June 2023

JDRF announces new Board appointments

We’re pleased to announce the appointment of two new Board Directors, Nadia Swann and Sarah Johnson.

Read more
JDRF's 2022 in review
JDRF
21 December 2022

Our 2022 Year in Review

A lot has happened over the last 12 months at JDRF, and in the world of type 1 diabetes as a whole. From research breakthroughs to herculean fundraising efforts, here’s a retrospective of everything we’ve been celebrating in 2022.

Read more
Terence Lovell, JDRF UK's fundraising and engagement director
JDRF
9 November 2022

JDRF UK appoints Terence Lovell as Fundraising and Engagement Director

We are delighted to welcome Terence Lovell as Director of Fundraising and Engagement. Terence has worked in the not-for-profit sector for over 20 years.